Molecular Partners Ag (MOLN) EBT Margin (2020 - 2024)
Molecular Partners Ag's (MOLN) quarterly EBT Margin came in at 224.82% in Q4 2024, up 5646.0% year-over-year from 3.91% in Q1 2024, and up 99.99% quarter-over-quarter from 2408810.57% in Q3 2024.
Powered by 
Analysis
Molecular Partners Ag (MOLN) EBT Margin (2020 - 2024) Analysis & Trends
Molecular Partners Ag (MOLN) has reported EBT Margin for 5 consecutive years, with 224.82% the latest figure, recorded in Q4 2024.
- On a quarterly basis, EBT Margin rose 5646.0% year-over-year to 224.82% in Q4 2024; TTM through Jun 2026 was 1132.09%, a 12039.0% decrease from a year earlier, with the FY2024 full-year figure at 1080.82%, down 20012.0% from the prior year.
- EBT Margin was 224.82% for Q4 2024 at Molecular Partners Ag, up from 2408810.57% in the prior quarter.
- Over five years, EBT Margin peaked at 5820848.06% in Q3 2020 and troughed at 2408810.57% in Q3 2024.
- A 5-year average of 25612.91% and a median of 1043.08% in 2024 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin sank 616924885 bps in 2021 and jumped 178299440 bps in 2022, its largest moves.
- Over 5 years, EBT Margin stood at 1113.76% in 2020, then surged by 84 bps to 183.74% in 2021, then surged by 95 bps to 9.2% in 2022, then slumped by 2957 bps to 281.29% in 2023, then climbed by 20 bps to 224.82% in 2024.
- The last three EBT Margin figures came in at 224.82% (Q4 2024), 2408810.57% (Q3 2024), and 972.4% (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,427.46% |
| 10 | Molecular Partners Ag | 156.54 Mn | 156.54 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -224.82% |
| Sep 30, 2024 | -2,408,810.57% |
| Jun 30, 2024 | -972.40% |
| Mar 31, 2024 | -413,623.08% |
| Dec 31, 2023 | -281.29% |
| Sep 30, 2023 | -450,177.10% |
| Jun 30, 2023 | -3,852.29% |
| Mar 31, 2023 | -484,524.59% |
| Dec 31, 2022 | -9.20% |
| Sep 30, 2022 | -563,536.38% |
| Jun 30, 2022 | -38.46% |
| Mar 31, 2022 | 88,623.88% |
| Dec 31, 2021 | -183.74% |
| Sep 30, 2021 | -348,400.79% |
| Jun 30, 2021 | -385.26% |
| Mar 31, 2021 | -1,694,370.52% |
| Dec 31, 2020 | -1,113.76% |
| Sep 30, 2020 | 5,820,848.06% |